Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
No Thumbnail Available
Identifiers
Date
2021-11-18
Authors
Marth, Christian
Tarnawski, Rafal
Tyulyandina, Alexandra
Pignata, Sandro
Gilbert, Lucy
Kaen, Diego
Rubio, M. Jesus
Frentzas, Sophia
Beiner, Mario
Magallanes-Maciel, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bmj publishing group
Metrics
Export
Abstract
Background Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after